CFTR partnership Antiverse is actively developing antibodies targeting CFTR extracellular regions and has a collaboration with the Cystic Fibrosis Foundation, presenting a clear entry point for near-term partnerships or co-development deals in CF therapies.

AI design edge With an AI-driven antibody design platform trained on difficult targets like GPCRs and ion channels, Antiverse offers a differentiated value proposition for sponsors seeking faster hit generation and de novo antibody discovery against challenging targets.

Series A momentum Recent $9.3M Series A funding from a diverse set of investors signals growth readiness and potential for strategic partnerships, licensing, or collaboration deals to scale programs and expand capabilities.

Global footprint Headquartered in Cardiff with a Boston office, Antiverse is positioned to engage with both UK/EU and US collaborators, enabling multi-regional trials, access to diverse talent pools, and cross-border partnerships.

Public-private interest Recent government and regional investments highlighting support for AI-driven biotech suggest favorable funding climates for industry partnerships, joint ventures, and grant-aligned collaborations to accelerate antibody programs.